Comparison Log
2026-04-12 09:34:02.756388
mwtab Python Library Version: 2.0.0
Source:      https://www.metabolomicsworkbench.org/rest/study/analysis_id/AN007919/mwtab/...
Study ID:    ST004689
Analysis ID: AN007919
Status:      Inconsistent

Sections "STUDY" contain missmatched items: {'STUDY_SUMMARY': ["Understanding the biological mechanisms behind fracture nonunions and their treatments remains incomplete. Since these mechanisms are linked to the phenotypic expression, studying the longitudinal metabolic profile of bone regeneration has emerged as a potential way to better understand the healing progress and treatment effectiveness. In this study, we tracked the serum metabolome of rats with critically-sized femoral defects treated with either a control, a minimum effective dose, or a supraphysiologic dose of rhBMP-2 over time. We observed distinct changes in the metabolome across control, impaired healing, and recombinant human bone morphologic protein (rhBMP-2) treated animals. Early in the process, we saw increased levels of metabolites that support angiogenesis in the rhBMP-2 groups. Supraphysiologic doses of rhBMP-2 significantly affected metabolite expression, especially in pathways related to angiogenesis, fatty acid metabolism, and ATP production. These longitudinal trends and individual metabolite changes provide a deeper understanding of rhBMP-2's mechanisms, improve our knowledge of its biological effects--guiding appropriate dosing--and offer a metabolic profile that may indicate healing impairment.", "Understanding the biological mechanisms behind fracture nonunions and their treatments remains incomplete. Since these mechanisms are linked to the phenotypic expression, studying the longitudinal metabolic profile of bone regeneration has emerged as a potential way to better understand the healing progress and treatment effectiveness. In this study, we tracked the serum metabolome of rats with critically-sized femoral defects treated with either a control, a minimum effective dose, or a supraphysiologic dose of rhBMP-2 over time. We observed distinct changes in the metabolome across control, impaired healing, and recombinant human bone morphologic protein (rhBMP-2) treated animals. Early in the process, we saw increased levels of metabolites that support angiogenesis in the rhBMP-2 groups. Supraphysiologic doses of rhBMP-2 significantly affected metabolite expression, especially in pathways related to angiogenesis, fatty acid metabolism, and ATP production. These longitudinal trends and individual metabolite changes provide a deeper understanding of rhBMP-2''s mechanisms, improve our knowledge of its biological effects--guiding appropriate dosing--and offer a metabolic profile that may indicate healing impairment."]}
Sections "COLLECTION" contain missmatched items: {'COLLECTION_SUMMARY': ["Samples were vortexed and centrifuged to separate samples' cell pellet and supernatant layers before undergoing separate extraction methods. The residual BD SurePathTM liquid-based Pap test samples (~2 mL each) were transferred to 2 mL microcentrifuge tubes. Samples were vortexed for 10s followed by centrifugation at approximately 7,130 x g (5000 rpm) for 5 minutes to pellet the cells. Supernatants were removed and saved for further analysis.", "Samples were vortexed and centrifuged to separate samples'' cell pellet and supernatant layers before undergoing separate extraction methods. The residual BD SurePathTM liquid-based Pap test samples (~2 mL each) were transferred to 2 mL microcentrifuge tubes. Samples were vortexed for 10s followed by centrifugation at approximately 7,130 x g (5000 rpm) for 5 minutes to pellet the cells. Supernatants were removed and saved for further analysis."]}
Sections "PROJECT" contain missmatched items: {'PROJECT_SUMMARY': ["Understanding the biological mechanisms behind fracture nonunions and their treatments remains incomplete. Since these mechanisms are linked to the phenotypic expression, studying the longitudinal metabolic profile of bone regeneration has emerged as a potential way to better understand the healing progress and treatment effectiveness. In this study, we tracked the serum metabolome of rats with critically-sized femoral defects treated with either a control, a minimum effective dose, or a supraphysiologic dose of recombinant human bone morphologic protein (rhBMP-2) over time. We observed distinct changes in the metabolome across control, impaired healing, and rhBMP-2 treated animals. Early in the process, we saw increased levels of metabolites that support angiogenesis in the rhBMP-2 groups. Supraphysiologic doses of rhBMP-2 significantly affected metabolite expression, especially in pathways related to angiogenesis, fatty acid metabolism, and ATP production. These longitudinal trends and individual metabolite changes provide a deeper understanding of rhBMP-2's mechanisms, improve our knowledge of its biological effects--guiding appropriate dosing--and offer a metabolic profile that may indicate healing impairment.", "Understanding the biological mechanisms behind fracture nonunions and their treatments remains incomplete. Since these mechanisms are linked to the phenotypic expression, studying the longitudinal metabolic profile of bone regeneration has emerged as a potential way to better understand the healing progress and treatment effectiveness. In this study, we tracked the serum metabolome of rats with critically-sized femoral defects treated with either a control, a minimum effective dose, or a supraphysiologic dose of recombinant human bone morphologic protein (rhBMP-2) over time. We observed distinct changes in the metabolome across control, impaired healing, and rhBMP-2 treated animals. Early in the process, we saw increased levels of metabolites that support angiogenesis in the rhBMP-2 groups. Supraphysiologic doses of rhBMP-2 significantly affected metabolite expression, especially in pathways related to angiogenesis, fatty acid metabolism, and ATP production. These longitudinal trends and individual metabolite changes provide a deeper understanding of rhBMP-2''s mechanisms, improve our knowledge of its biological effects--guiding appropriate dosing--and offer a metabolic profile that may indicate healing impairment."], 'FUNDING_SOURCE': ["National Institutes of Health's National Center for Advancing Translational Sciences", "National Institutes of Health''s National Center for Advancing Translational Sciences"]}